BERKELEY HEIGHTS, NJ - November 29, 2004 -
Genta Incorporated (Nasdaq: GNTA) announced today that Genasense®
(oblimersen sodium) Injection, the Company's lead anticancer
compound, and Ganite® (gallium nitrate injection) will be featured
in several presentations at the annual meeting of the American
Society of Hematology (ASH) in San Diego, CA from December 3-7,
2004. Investigators will discuss study results in a variety of
hematological cancers, including chronic lymphocytic leukemia
(CLL), non-Hodgkin's lymphoma, acute myeloid leukemia, and multiple
myeloma. Several other presentations related to the Company's
current programs for CLL will be discussed and are also noted.
Highlighted presentations include the following:
- Friday, December 3, 2004; 8:00-11:00 a.m.
Restoring Pathways of Apoptosis in Hematologic Malignancies:
Exploring the Science,
Synergies, and Applications for Successful Therapies
Meeting Chair: Dr. Julie Vose; Speakers: Dr. Francine Foss, Dr.
Ruben Niesvizky, Dr.
Lawrence Piro and Dr. John Rossi
- Saturday, December 4, 2004; 6:00-7:30 p.m., Abstract # 1477
Randomized Multicenter Phase 3 Trial of High-Dose
Dexamethasone (dex) with or without Oblimersen Sodium (G3139;
Bcl-2 antisense; Genasense) for Patients with Advanced Multiple
Myeloma (MM)
Dr. Asher Chanan-Khan, Roswell Park Cancer Institute
- Saturday, December 4, 2004; 6:00-7:30 p.m., Abstract # 865
Phase 2 Study of Oblimersen Sodium (G3139; Bcl-2 Antisense;
Genasense®) plus Gemtuzumab Ozogamcin (Mylotarg®) in Elderly
Patients with Relapsed Acute Myeloid Leukemia
Dr. Joseph Moore, Duke University Medical Center
- Saturday, December 4, 2004, 6:00-7:30 p.m., Abstract # 1398
In Vivo Downregulation of Bcl-2 by G3139 Enhances Rituximab
Anti-Tumor Activity: Effect of Sequential Versus Concurrent G3139
Administration on Survival in a Lymphoma-Bearing SCID Mouse
Model
Dr. Jeyanthi Ramanarayanan, Roswell Park Cancer Institute
- Saturday, December 4, 2004; 6:00-7:30 p.m., Abstract # 956
Critical Molecular Studies to Strategically Plan Therapy in
Chronic Lymphocytic Leukemia (CLL): Correlating Cellular Proteins
with Defined Prognostic Patient Subsets and Their Response to
Treatment
Dr. Shinichi Kitada, The Burnham Institute
- Saturday, December 4, 2004; 6:00-7:30 p.m., Abstract # 1170
Intracellular Levels of Oblimersen Sodium and Target
Downregulation Correlate to Clinical Activity of Bcl-2 Antisense
in Acute Myeloid Leukemia
Dr. Guido Marcucci, The Comprehensive Cancer Center, Ohio State
University
- Sunday, December 5, 2004; 6:00-7:30 p.m., Abstract # 2407
A Phase I Trial of Oblimersen Sodium for Relapsed or
Refractory Waldenstrom's Macroglobulinemia
Dr. Morie Gertz, Mayo Clinic, Rochester, NY
- Sunday, December 5, 2004; 6:00-7:30 p.m., Abstract # 2487
Phase 2 Multicenter Trial of Gallium Nitrate in Patients with
Advanced Non-Hodgkin's Lymphoma
Dr. Christopher R. Chitambar, Medical College of Wisconsin
- Sunday, December 5, 2004; 6:00-7:30 p.m., Abstract # 2400
Phase II Trial of Oblimersen Sodium (G3139), Dexamethasone
and Thalidomide in Relapsed Multiple Myeloma Patients
Dr. Ashrof Badros, Greenebaum Cancer Center, University of
Maryland
- Sunday, December 5, 2004; 6:00-7:30 p.m., Abstract # 2484
Combined Targeting of the Proteasome and Bcl-2 Sensitizes
Human B-Cell Lymphoma and Multiple Myeloma to Cyclophosphamide in
In Vitro and In Vivo Models of These Diseases
Dr. Owen O'Connor, Memorial Sloan Kettering Cancer Center
- Sunday, December 5, 2004; 6:00-7:30 p.m., Abstract #2294
Inhibition of Bcl-2 by Antisense Oligonucleotide and siRNA in
Specimens from Patients with Waldenstrom's Macroglobulinemia
Dr. Gwen L. Nichols, Columbia University
- Monday, December 6, 2004; 11:15 a.m., Abstract # 338
Phase 3 Randomized Trial of Fludarabine/Cyclophosphamide
Chemotherapy with or without Oblimersen Sodium (Bcl-2 Antisense;
Genasense; G3139) for Patients with Relapsed or Refractory
Chronic Lymphocytic Leukemia
Dr. Kanti Rai, Long Island Jewish Medical Center
- Monday, December 6, 2004; 1:30 p.m., Abstract # 475
Fludarabine and Cyclophosphamide Produces a Higher Complete
Response Rate and More Durable Remissions Than Fludarabine in
Patients with Previously Untreated CLL: Intergroup Trial
E2997
Dr. Ian W. Flinn, Eastern Cooperative Oncology Group (ECOG)
- Abstract # 4827, published in Blood (Supplement)
A Pilot Study of Genasense (Oblimersen Sodium, Bcl-2
Antisense Oligonucleotide), Fludarabine and Rituximab in
Previously Treated and Untreated Subjects with Chronic
Lymphocytic Leukemia
Dr. Asher Chanan-Khan, Roswell Park Cancer Institute
About Genta
Genta Incorporated is a pharmaceutical company with a diversified
product portfolio that is focused on delivering innovative
products for the treatment of patients with cancer. The Company's
research platform is anchored by two major programs that center
on oligonucleotides (RNA and DNA-based medicines) and small
molecules. Genasense® (oblimersen sodium) Injection, the
Company's lead compound from its oligonucleotide program, is
currently undergoing late-stage, Phase 3 clinical testing. The
leading drug in Genta's small molecule program is Ganite®
(gallium nitrate injection), which the Company is exclusively
marketing in the U.S. for treatment of patients with
cancer-related hypercalcemia that is resistant to hydration. For
more information about Genta, please visit our website at:
http://www.genta.com/
.
This press release contains forward-looking statements with
respect to business conducted by Genta Incorporated. By their
nature, forward-looking statements and forecasts involve risks
and uncertainties because they relate to events and depend on
circumstances that will occur in the future. There are a number
of factors that could cause actual results and developments to
differ materially. For a discussion of those risks and
uncertainties, please see the Company's Annual Report/Form 10-K
for 2003. SOURCE: Genta Incorporated
